Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Added to the ICE Biotechnology Index
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
Tickers TSHA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.